Mereo BioPharma FY2024 net loss $43.3M; cash $69.8M funds operations into 2027

Mereo BioPharma Group plc

Net loss of $43.3M in FY2024 vs $29.5M in FY2023; R&D expenses rose $3.5M to $20.9M driven by alvelestat and setrusumab.
Cash and equivalents of $69.8M as of Dec 31, 2024; expected to fund operations into 2027.
Phase 3 Orbit study of setrusumab in OI progressing; second interim analysis expected mid-2025, final Q4 2025.
Alvelestat granted EU Orphan Designation for AATD-LD in Q1 2025; partnering discussions ongoing.
Pre-commercial activities for setrusumab in Europe advancing with NICE and GBA scientific advice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.